Premenstrual syndrome (PMS) encompasses recurrent physical, emotional, and behavioural symptoms in the luteal phase that remit with menstruation. PMDD represents a severe variant with marked mood disturbance and functional impairment, aligned with DSM-5 and ICD-11 criteria.
Assessment
Structured prospective daily symptom charting over at least two cycles is the cornerstone of diagnosis, alongside menstrual history and exclusion of other conditions (e.g., mood disorders, thyroid issues). NICE and RCOG materials emphasise this approach, yet implementation varies. Misattribution to stress or personality traits without cycle tracking remains a noted challenge.
Management principles
Shared decision-making is essential. Options include lifestyle measures, cognitive behavioural therapy (CBT), SSRIs (continuous or luteal-phase), combined oral contraceptives (particularly drospirenone-containing), and, in severe refractory cases, GnRH analogues or surgical options with HRT. Evidence supports efficacy of targeted SSRIs and specific hormonal preparations.
Medication masking effects
Hormonal agents can suppress ovulation and alter symptom cyclicity. Mood-stabilising or analgesic therapies may blunt expression of symptoms, potentially delaying pattern recognition if menstrual history is not revisited. Fragmented prescribing across specialties heightens this risk. Regular review and holistic documentation are recommended.
Perinatal context
Symptoms typically remit in pregnancy. Postnatal history-taking should include prior premenstrual disorders due to potential vulnerability. Perinatal mental health pathways should integrate menstrual context.
Evidence base and limitations
Prevalence estimates for moderate-severe PMS range widely (up to 30-40% in some studies); PMDD around 1.6-8% depending on criteria. UK data coding limitations hinder precise epidemiology. Underrepresentation of diverse groups persists. Royal Colleges continue to strengthen training, supported by the Women’s Health Strategy.
Improving practice
Consistent menstrual history-taking in mood presentations, integration of validated tracking tools, clear referral pathways, and multidisciplinary liaison (primary care, gynaecology, mental health) are key. Audits of documentation and follow-up would support quality improvement.
Questions for clinicians
- How consistently is prospective tracking initiated and documented?
- How are medication effects on cyclicity reviewed?
- What local pathways support seamless transitions?
This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed.
This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.
References
- RCOG Green-top Guideline No. 48.
- NICE Clinical Knowledge Summaries: PMS.
- Women’s Health Strategy for England.
- NAPS Guidelines on Premenstrual Syndrome.